Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue ( @entity1074 ) with @entity2664 , XXXX and @entity229 (MCP).

@entity1 @entity137 @entity706 @entity6595 @entity1074 @entity229 @entity2664 @entity5805 @entity281 @entity3028
BACKGROUND: Mucosa-associated lymphoid tissue (MALT) @entity706 is a relatively common @entity706 arising in various tissues throughout the @entity1 body. Currently, there is no standard chemotherapy for advanced stage @entity1074 . This has prompted us to retrospectively analyse our experience with the MCP regimen ( @entity2664 , @entity5805 and @entity229 ) in @entity1 with @entity1074 . @entity1 AND METHODS: @entity1 with histologically verified @entity1074 undergoing chemotherapy with MCP were evaluated retrospectively. The MCP regimen consists of @entity2664 8 mg/m(2) intravenously on days 1 and 2, @entity5805 3 x 3 mg/m(2) per os (p.o.) on days 1-5 and @entity229 25 mg/m(2) p.o. on days 1-5. Information analysed included localisation of the @entity706 , clinical stage, pretreatment, number of chemotherapy cycles administered, @entity137 , response to treatment, follow-up time, relapse and survival. RESULTS: A total of 15 @entity1 (six females and nine males aged between 34 and 88 years) with histologically ascertained @entity1074 undergoing treatment with the MCP regimen were identified from our records. Ten @entity1 had @entity706 , while five @entity1 suffered from @entity6595 . All @entity1 were chemotherapy-na  ve, while two had been locally irradiated before application of MCP for recurrent disease. A total of 74 cycles was administered to our @entity1 , with a median number of five cycles per @entity1 . Eight (53%) @entity1 achieved complete remission, six (40%) @entity1 partial response and only one (7%) @entity1 had progressive disease. Subjective tolerance was excellent, and @entity137 were mainly haematological, including @entity3028 World Health Organisation grade 3 and 4 in three @entity1 each. In two @entity1 , this was accompanied by single episodes of @entity281 . At the time of analysis, all @entity1 are still alive. No relapses have occurred after a median follow-up time of 16 (range 12-29) months. CONCLUSIONS: Our data suggest that MCP is an effective and well-tolerated regimen for treatment of @entity1 with @entity1074 irrespective of localisation. Judging from our data, MCP also appears to be a feasible regimen in elderly @entity1 .
